| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.11. | Isofol Medical AB: Isofol provides a new update on the ongoing phase Ib/II clinical study of arfolitixorin | 235 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, November 10, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today provides an update on the company's ongoing phase Ib/II clinical study of arfolitixorin in patients... ► Artikel lesen | |
| ISOFOL MEDICAL Aktie jetzt für 0€ handeln | |||||
| 25.08. | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January - June 2026 | 247 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, August 25, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's interim report for January - June 2026 is... ► Artikel lesen | |
| 24.08. | Isofol Medical AB: Isofol expands the number of study sites to accelerate patient recruitment in cancer study | 293 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, August 24, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the company includes additional clinical trial sites to the ongoing phase Ib/II study with... ► Artikel lesen | |
| 08.07. | Isofol Medical AB: Isofol initiates last dose cohort in ongoing phase Ib study with arfolitixorin | 595 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, July 8, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has completed the third dose level in the dose-escalation part of the phase... ► Artikel lesen | |
| 19.05. | Isofol Medical AB: Bulletin from annual general meeting in Isofol Medical AB (publ) held on 19 May, 2026 | 571 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, May 19, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) (the "Company") held its annual general meeting (the "AGM") today. The following resolutions, in principle, were... ► Artikel lesen | |
| 19.05. | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January - March 2026 | 362 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, May 19, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's interim report for January - March 2026 is now... ► Artikel lesen | |
| 15.04. | Isofol Medical AB: Isofol optimizes the design of its phase Ib/II study following new regulatory approval | 716 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, April 15, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the German regulatory authority BfArM has approved an optimized design for the company's... ► Artikel lesen | |
| 18.03. | Isofol Medical AB: Isofol secures license rights for arfolitixorin in autism | 1.012 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, March 18, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the company has expanded its global exclusive license agreement for arfolitixorin to also... ► Artikel lesen | |
| 11.03. | Isofol Medical AB: Isofol receives top guarantee commitment and letters of intent corresponding to 42 percent of upcoming warrant exercise | 523 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, 11 March 2026 - Isofol Medical AB ("Isofol" or the "Company") announces today that the Company has received a top guarantee commitment from existing shareholder Solasia Pharma K.K.... ► Artikel lesen | |
| 24.02. | Isofol Medical AB: Isofol provides update on the ongoing phase Ib/II clinical study of arfolitixorin | 916 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, February 24, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today provides an update on the company's ongoing phase Ib/II clinical study of arfolitixorin, which is initially... ► Artikel lesen | |
| 18.02. | Isofol Medical AB: Isofol Medical AB (publ) publishes year-end report, January - December 2025 | 340 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, February 18, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's year-end report for January - December 2025... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,411 | -1,23 % | Valneva-Aktie über der 50-Tage-Linie: Positive Shigella-Daten treiben an | ||
| INTELLIA THERAPEUTICS | 8,880 | -0,34 % | Intellia auf der Jefferies Global Healthcare Conference: Marktstart und Pipeline im Fokus | ||
| CARDIOL THERAPEUTICS | 0,873 | +0,81 % | Bayer, Cardiol Therapeutics, Novartis - Biotech-Aktien und Pharmariesen im Wettlauf ums Herz | Erstellt und veröffentlicht im Auftrag von Cardiol Therapeutics Die Kardiologie gehört zu den spannendsten Feldern der Pharmabranche. Vier Tage in Chicago haben gezeigt, wie viel Bewegung in der Herzmedizin... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,800 | +7,63 % | Pacific BioSciences of California (NDQ:PACB): After a Horror 2 Years, Is This Company About To Reach Its Inflection Point | ||
| BIOMERIEUX | 90,45 | 0,00 % | Was der Markt bei bioMérieux übersah! | ||
| BIO GREEN MED SOLUTION | 0,583 | +1,43 % | Bio Green Med Solution declares $0.15 dividend | ||
| ANAPTYSBIO | 40,770 | -4,99 % | AnaptysBio GAAP EPS of $0.11 misses by $0.28, revenue of $30.27M misses by $3.19M | ||
| GENUS | 27,000 | -1,46 % | Dividendenbekanntmachungen (12.11.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AEBI SCHMIDT HOLDING AG CH0027352993 0,025 USD 0,0225 EUR AIRTEL AFRICA PLC GB00BKDRYJ47 0,031 USD 0,0279 EUR ALLWYN AG GRS419003009 - ... ► Artikel lesen | |
| AKESO | 6,796 | +0,59 % | CMBI Cuts AKESO TP to HKD99.34; HARMONi-3 Remains Key Catalyst | ||
| MEIRAGTX | 8,150 | +7,95 % | MeiraGTx Announces Oral Presentation at ObesityWeek 2026 | ||
| XTL BIOPHARMACEUTICALS | 1,610 | 0,00 % | XTL BioPharmaceuticals GAAP EPS of $0.00 | ||
| ABIONYX PHARMA | 1,530 | 0,00 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| MAAT PHARMA | 0,871 | 0,00 % | MaaT Pharma Reports Financial Results for the Third Quarter 2026 | Revenues of EUR 0.5 million in the third quarter of 2026 and EUR 1.6 million year-to-date, derived from the Early Access Program
As of September 30, 2026, cash and cash equivalents were... ► Artikel lesen | |
| QIAGEN | 45,200 | 0,00 % | QIAGEN N.V.: QIAGEN-Aktionäre stimmen der Berufung von Jonathan M. Pratt in die Geschäftsführung mit überwältigender Mehrheit zu | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute bekannt gegeben, dass die Aktionärinnen und Aktionäre auf einer Außerordentlichen Hauptversammlung der Berufung von Jonathan M. Pratt... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 10,500 | 0,00 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence |